Trade Merck & Co Inc - USD - MRK CFD

Add to favourite

125.12

0.15%

0.14

Low: 124.56

High: 125.14

Market Trading Hours* (UTC) Opens on Friday at 13:30

Mon - Fri: 13:30 - 20:00

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.14

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Merck & Co Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	125.31
Open*	124.91
1-Year Change*	8.72%
Day's Range*	124.56 - 125.14
52 wk Range	99.14-119.94
Average Volume (10 days)	7.80M
Average Volume (3 months)	172.98M
Market Cap	300.38B
P/E Ratio	65.68
Shares Outstanding	2.53B
Revenue	59.31B
EPS	1.80
Dividend (Yield %)	2.59828
Beta	0.38
Next Earnings Date	Feb 1, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	125.12	0.21	0.17%	124.91	125.35	124.45
Apr 17, 2024	125.31	0.23	0.18%	125.08	126.12	124.65
Apr 16, 2024	124.99	-0.93	-0.74%	125.92	126.49	124.73
Apr 15, 2024	126.11	-0.03	-0.02%	126.14	127.76	125.69
Apr 12, 2024	125.30	-0.24	-0.19%	125.54	126.65	125.04
Apr 11, 2024	126.06	-0.20	-0.16%	126.26	127.07	125.38
Apr 10, 2024	126.64	1.29	1.03%	125.35	126.94	124.97
Apr 9, 2024	126.67	0.35	0.28%	126.32	126.85	125.45
Apr 8, 2024	126.54	-0.02	-0.02%	126.56	127.76	125.82
Apr 5, 2024	127.91	0.45	0.35%	127.46	128.54	126.87
Apr 4, 2024	127.58	-2.42	-1.86%	130.00	130.69	127.24
Apr 3, 2024	129.84	-0.47	-0.36%	130.31	132.23	129.24
Apr 2, 2024	130.30	0.34	0.26%	129.96	130.60	129.20
Apr 1, 2024	130.83	-0.63	-0.48%	131.46	131.80	130.04
Mar 28, 2024	131.89	0.08	0.06%	131.81	132.27	130.98
Mar 27, 2024	131.67	0.51	0.39%	131.16	132.94	130.04
Mar 26, 2024	125.47	0.42	0.34%	125.05	126.01	124.76
Mar 25, 2024	125.27	1.26	1.02%	124.01	125.51	123.71
Mar 22, 2024	123.80	0.73	0.59%	123.07	124.40	123.03
Mar 21, 2024	123.51	0.34	0.28%	123.17	124.13	122.98

Merck & Co Inc - USD Events

Time (UTC)	Country	Event
Thursday, April 25, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Merck & Co Inc Earnings Release Q1 2024 Merck & Co Inc Earnings Release Forecast - Previous -
Time (UTC) 13:00	Country US	Event Q1 2024 Merck & Co Inc Earnings Call Q1 2024 Merck & Co Inc Earnings Call Forecast - Previous -
Wednesday, May 22, 2024
Time (UTC) 13:00	Country US	Event Merck & Co Inc Annual Shareholders Meeting Merck & Co Inc Annual Shareholders Meeting Forecast - Previous -
Tuesday, May 28, 2024
Time (UTC) 13:00	Country US	Event Merck & Co Inc Annual Shareholders Meeting Merck & Co Inc Annual Shareholders Meeting Forecast - Previous -
Tuesday, July 30, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 Merck & Co Inc Earnings Release Q2 2024 Merck & Co Inc Earnings Release Forecast - Previous -
Time (UTC) 13:00	Country US	Event Q2 2024 Merck & Co Inc Earnings Call Q2 2024 Merck & Co Inc Earnings Call Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	59283	48704	41518	39121	42294
Revenue	59283	48704	41518	39121	42294
Cost of Revenue, Total	17206	13241	11583	11060	13065
Gross Profit	42077	35463	29935	28061	29229
Total Operating Expense	41338	36166	36545	31821	33995
Selling/General/Admin. Expenses, Total	9948	9615	8908	9421	10067
Research & Development	11818	10281	10102	8555	7854
Unusual Expense (Income)	2366	3029	5952	2785	3009
Operating Income	17945	12538	4973	7300	8299
Interest Income (Expense), Net Non-Operating	-2461	873	421	-636	10
Other, Net	960	468	469	507	392
Net Income Before Taxes	16444	13879	5863	7171	8701
Net Income After Taxes	14526	12358	4523	5606	6482
Minority Interest	-7	-13	-4	84	27
Net Income Before Extra. Items	14519	12345	4519	5690	6509
Net Income	14519	13049	7067	9843	6220
Income Available to Common Excl. Extra. Items	14519	12345	4519	5690	6509
Income Available to Common Incl. Extra. Items	14519	13049	7067	9843	6220
Diluted Net Income	14519	13049	7067	9843	6220
Diluted Weighted Average Shares	2542	2538	2541	2580	2679
Diluted EPS Excluding Extraordinary Items	5.71164	4.86407	1.77843	2.20543	2.42964
Dividends per Share - Common Stock Primary Issue	2.8	2.64	2.48	2.26	1.99
Diluted Normalized EPS	7.89442	6.81007	4.69927	3.96379	4.13343
Total Extraordinary Items	0	704	2548	4153	-289

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total revenue	15962	15035	14487	13830	14959
Revenue	15962	15035	14487	13830	14959
Cost of Revenue, Total	3679	3992	3897	3843	3880
Gross Profit	12283	11043	10590	9987	11079
Total Operating Expense	10192	20198	10175.5	10392	10947
Selling/General/Admin. Expenses, Total	2462	2625	2478	2667	2494
Research & Development	3297	13320	4276	2962	3511
Unusual Expense (Income)	754	261	-475.5	920	1062
Operating Income	5770	-5163	4311.5	3438	4012
Interest Income (Expense), Net Non-Operating	-17	-405	259	-215	-671
Other, Net	-133	233	-920.5	290	242
Net Income Before Taxes	5620	-5335	3650	3513	3583
Net Income After Taxes	4750	-5972	2825	3018	3253
Minority Interest	-5	-3	-4	-1	-5
Net Income Before Extra. Items	4745	-5975	2821	3017	3248
Total Extraordinary Items				0	0
Net Income	4745	-5975	2821	3017	3248
Income Available to Common Excl. Extra. Items	4745	-5975	2821	3017	3248
Income Available to Common Incl. Extra. Items	4745	-5975	2821	3017	3248
Diluted Net Income	4745	-5975	2821	3017	3248
Diluted Weighted Average Shares	2546	2539	2541	2548	2542
Diluted EPS Excluding Extraordinary Items	1.86371	-2.35329	1.11019	1.18407	1.27773
Dividends per Share - Common Stock Primary Issue	0.73	0.73	0.73	0.73	0.69
Diluted Normalized EPS	2.19324	-2.15898	1.14507	1.94001	2.1663

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	35722	30266	27764	27483	25875
Cash and Short Term Investments	13192	8096	8062	10450	8864
Cash & Equivalents	12694	8096	8062	9676	7965
Short Term Investments	498		0	774	899
Total Receivables, Net	10110	9230	7851	6778	7071
Accounts Receivable - Trade, Net	9450	9230	7851	6778	7071
Total Inventory	5911	5953	6310	5978	5440
Other Current Assets, Total	6509	6987	5541	4277	4500
Total Assets	109160	105694	91588	84397	82637
Property/Plant/Equipment, Total - Net	22768	19279	17986	16126	13291
Property/Plant/Equipment, Total - Gross	40753	37471	36968	33812	29615
Accumulated Depreciation, Total	-17985	-18192	-18982	-17686	-16324
Goodwill, Net	21204	21264	20238	19425	18253
Intangibles, Net	20269	22933	14604	14196	11431
Long Term Investments	2445	966	1371	1889	6233
Other Long Term Assets, Total	6752	10986	9625	5278	7554
Total Current Liabilities	24239	23872	27327	22220	22206
Accounts Payable	4264	4609	4594	3738	3318
Accrued Expenses	13608	13859	13053	12453	10073
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	1946	2412	6431	3610	5308
Other Current Liabilities, Total	4421	2992	3249	2419	3507
Total Liabilities	63169	67510	66271	58490	55936
Total Long Term Debt	28745	30690	25360	22736	19806
Long Term Debt	28745	30690	25360	22736	19806
Deferred Income Tax	1795	3441	1015	1470	1702
Minority Interest	67	73	87	94	181
Other Liabilities, Total	8323	9434	12482	11970	12041
Total Equity	45991	38184	25317	25907	26701
Common Stock	1788	1788	1788	1788	1788
Additional Paid-In Capital	44379	44238	39588	39660	38808
Retained Earnings (Accumulated Deficit)	61081	53696	47362	46602	42579
Treasury Stock - Common	-56489	-57109	-56787	-55950	-50929
Unrealized Gain (Loss)	0	0	0	18	-78
Other Equity, Total	-4768	-4429	-6634	-6211	-5467
Total Liabilities & Shareholders’ Equity	109160	105694	91588	84397	82637
Total Common Shares Outstanding	2537.83	2527.6	2530.23	2539.02	2592.56

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	31954	29977	33402	35722	33561
Cash and Short Term Investments	8773	6378	10387	13192	11248
Cash & Equivalents	8605	5660	9707	12694	11145
Total Receivables, Net	11485	11748	11104	10110	10118
Accounts Receivable - Trade, Net	10394	11030	10415	9450	9482
Total Inventory	6131	5930	5863	5911	5614
Other Current Assets, Total	5565	5921	6048	6509	6581
Total Assets	106727	104469	107796	109160	107081
Property/Plant/Equipment, Total - Net	22526	22231	21758	21422	20424
Property/Plant/Equipment, Total - Gross	40972	40663	40014	39407	38345
Accumulated Depreciation, Total	-18446	-18432	-18256	-17985	-17921
Goodwill, Net	21183	21195	21209	21204	21160
Intangibles, Net	19199	19665	19857	20269	21368
Long Term Investments	2636	2785	2957	2445	2344
Other Long Term Assets, Total	9229	8616	8613	8098	8224
Total Current Liabilities	23094	23394	23131	24239	22998
Accounts Payable	3509	3442	3680	4264	3371
Accrued Expenses	14134	13375	12595	13608	13941
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	887	2839	2672	1946	1936
Other Current Liabilities, Total	4564	3738	4184	4421	3750
Total Liabilities	65481	65776	60962	63169	62623
Total Long Term Debt	33972	34072	28074	28745	28482
Long Term Debt	33972	34072	28074	28745	28482
Deferred Income Tax	1018	996	1442	1795	2417
Minority Interest	54	49	71	67	66
Other Liabilities, Total	7343	7265	8244	8323	8660
Total Equity	41246	38693	46834	45991	44458
Common Stock	1788	1788	1788	1788	1788
Additional Paid-In Capital	44358	44219	44467	44379	44243
Retained Earnings (Accumulated Deficit)	57082	54198	62039	61081	59928
Treasury Stock - Common	-57066	-56612	-56577	-56489	-56758
Unrealized Gain (Loss)				0
Other Equity, Total	-4916	-4900	-4883	-4768	-4743
Total Liabilities & Shareholders’ Equity	106727	104469	107796	109160	107081
Total Common Shares Outstanding	2535.29	2539.43	2537.45	2537.83	2533.41
Short Term Investments	168	718	680	498	103

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	14526	12358	4523	9777	6193
Cash From Operating Activities	19095	14109	10253	13440	10922
Cash From Operating Activities	1824	1578	1669	3652	4519
Deferred Taxes	-1568	187	-566	-556	-509
Non-Cash Items	5010	2189	7411	2634	2272
Cash Taxes Paid	3200	2400	2700	4500	1500
Cash Interest Paid	937	779	822	841	777
Changes in Working Capital	-2782	-3839	-4601	-2067	-1553
Cash From Investing Activities	-4960	-16555	-9443	-2629	4314
Capital Expenditures	-4388	-4448	-4429	-3473	-2615
Other Investing Cash Flow Items, Total	-572	-12107	-5014	844	6929
Cash From Financing Activities	-9119	2593	-2832	-8861	-13160
Financing Cash Flow Items	-240	8210	-436	5	-325
Total Cash Dividends Paid	-7012	-6610	-6215	-5695	-5172
Issuance (Retirement) of Stock, Net	384	-638	-1192	-4419	-8500
Issuance (Retirement) of Debt, Net	-2251	1631	5011	1248	837
Foreign Exchange Effects	-410	-133	253	17	-205
Net Change in Cash	4606	14	-1769	1967	1871
Amortization	2085	1636	1817

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	2825	14526	11508	8256	4307
Cash From Operating Activities	1339	19095	14665	9063	4761
Cash From Operating Activities	448	1824	1394	895	421
Amortization	543	2085	1623	1163	699
Deferred Taxes	-277	-1568	-1261	-600	-338
Non-Cash Items	690	5010	3836	2047	971
Cash Interest Paid	208	937	660	449	211
Changes in Working Capital	-2890	-2782	-2435	-2698	-1299
Cash From Investing Activities	-2359	-4960	-3212	-2250	-1173
Capital Expenditures	-1007	-4388	-3239	-2113	-984
Other Investing Cash Flow Items, Total	-1352	-572	27	-137	-189
Cash From Financing Activities	-2054	-9119	-7565	-4863	-3086
Financing Cash Flow Items	-81	-240	-172	-207	-103
Total Cash Dividends Paid	-1853	-7012	-5262	-3515	-1745
Issuance (Retirement) of Stock, Net	-119	384	119	109	12
Issuance (Retirement) of Debt, Net	-1	-2251	-2250	-1250	-1250
Foreign Exchange Effects	87	-410	-776	-364	-55
Net Change in Cash	-2987	4606	3112	1586	447

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Merck - USD Company profile

Merck & Co., Inc. (MRK) is a healthcare company dealing in pharmaceuticals and animal health. Founded in 1891, Merck is headquartered in Kenilworth, New Jersey.

The company provides pharmaceutical products around the world, offering an array of human healthcare solutions designed for areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular and diabetes.

Apart from prescription medicines, Merck is known for its vaccine products for preventive diseases. A predecessor company to the present-day Merck made the first smallpox vaccine for commercial use in the United States in 1898 and was the maker of HPV vaccine Gardasil and painkiller Vioxx.

This biopharmaceutical company engages in research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. In 2021, Merck invested $12.2bn in research and development, especially to counter and help win the fight against coronavirus. It’s molnupiravir was given emergency use authorisation by the United States Food and Drug Administration (FDA) to counter mild-to-moderate Covid-19 in adults.

Merck puts equal emphasis on animal health through Merck Animal Health, a research-driven company that develops, manufactures and markets a broad range of veterinary medicines and services.

The company engages and partners with several experts for early-stage science, clinical-stage programs, to deliver therapies and more. GlaxoSmithKline PLC (GSK), Johnson & Johnson (JJ) and many others are actively engaged with Merck.

Being more than a century old, Merck made it through two world wars and was a big part of the economic and business history of American public markets. Post-First World War, authorities seized the subsidiary of a German chemical maker to prevent the Kaiser from profiteering from American needs. Merck was re-established as an American corporation after the Second World War ended.

The company went public on the New York Stock Exchange in 1946 under the symbol ‘MRK’.

Industry:

Pharmaceuticals (NEC)

2000 Galloping Hill Road
KENILWORTH
NEW JERSEY 07033
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024